Sierra oncology, inc. (SRRA)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Operating expenses:
Research and development

53,249

41,078

30,157

33,895

26,356

19,078

2,843

General and administrative

13,743

14,339

12,462

14,180

9,472

3,500

1,162

Total operating expenses

66,992

55,417

42,619

48,075

35,828

22,578

4,005

Loss from operations

-66,992

-55,417

-42,619

-48,075

-35,828

-22,578

-4,005

Other income (expense), net:
Changes in fair value of warrant liabilities

20,926

-

-

-

17,443

1,380

202

Interest expense

-

-

-

-

-

-

2,719

Other income, net

-517

1,780

760

351

66

87

94

Total other income (expense), net

-21,443

1,780

760

-

-17,377

-1,293

-2,827

Loss before provision for (benefit from) income taxes, net

-88,435

-53,637

-41,859

-47,724

-53,205

-23,871

-6,832

Provision for (benefit from) income taxes, net

-160

-302

156

143

55

2

-

Net loss and comprehensive loss

-88,275

-53,335

-42,015

-47,867

-53,260

-23,873

-6,832

Adjustment to redemption value on redeemable convertible preferred stock

-

-

-

-

374,015

49,849

5,713

Net loss attributable to common stockholders

-

-

-

-

-453,184

-73,722

-12,545

Net loss per common share, basic and diluted

-30.30

-30.16

-33.68

-1.58

-31.47

-69.08

-19.18

Weighted-average shares used in computing net loss per common share, basic and diluted

2,913

1,768

1,247

30,240

14,399

1,067

653